Funding for the Depression Clinical and Research Program: Support for the Depression program advances patient care and treatment, physician education, and insures that forward-looking research continues to improve outcomes.
More About our Program
FUNDING FOR THE DEPRESSION CLINICAL AND RESEARCH PROGRAM
The Roger S. Goldstein FundThe Roger S. Goldstein Fund, a non-profit organziation, is a significant contributer to the Depression Clinical and Research Program at the Massachusetts General Hospital (MGH) and its campaign to educate physicians in the complex battle against depression. Every year, the Roger S. Goldstein Fund puts forth a depression awareness calender, which is a collaboration of 12 artists who have been touched by depression. All proceeds of the calender go directly toward the work of the Roger S. Goldstein Fund, which is dedicated to the education of internists to recognize and treat depression more effectively. The calendar is also, in and of itself, another way to disseminate information about depression. If you would like to order a calender a set of 12 notecards, please call 508-655-4187 or email RSGFund@comcast.net.
The Judith Brown Caro Fund for Depression Awareness and TreatmentJudith Brown Caro has a goal: to advance the understanding and treatment of depression. Depression is the most prevalent mental illness and in her words, is the "most lonely and silent disease." To reach her goal, Judy has set up at the hospital the Judith Brown Caro Fund for Depression Awareness and Treatment. Her hope is to educate people about the signs of depression and the need for timely and effective care. To this end, the fund will support the development of a DCRP newsletter, expand information offered on the DCRP website, support public lectures given by DCRP faculty, and conduct education and screening programs for the general public. If you share Judy's vision and value this work, contributions will be gratefully accepted. For further information, please contact Carol Taylor at 617 724 8799.
Donations to DCRPDepression is an illness associated with significant chronicity and disability, having a profound impact on the quality of life. Depression is currently the leading cause of disability in developed countries, and the fourth leading cause of disability worldwide.
Projections estimate that depression will rise to be the second leading cause disability worldwide by the year 2020. Depression has been shown to dramatically increase the degree of social disability, regardless of the quality of one’s physical health. In fact, the impact of depression on well-being is comparable to or greater than many chronic medical conditions.
Currently, the annual cost of depression to society in the US alone has been estimated at 70 to 80 billion dollars.
In addition to disability, depression has also been characterized by an increased risk of suicide, particularly in children and adolescents. In the last 50 years, the suicide rate for 15-19 year olds has tripled while the suicide rate for 10-14 year olds has doubled. Currently, suicide ranks as the third leading cause of death in adolescents.
In view of the debilitating impact of depression on the quality of life and the expected increase in disability worldwide, research is urgently needed to study new treatments aimed at improving the standard of care for depression. The DCRP is committed to the conduct of state of the art research in Depression. If you would like to personally contribute to this effort, please contact:
Maurizio Fava, M.D.
Director, Depression Clinical and Research Program
Massachusetts General Hospital